As the immune system weakens with age, researchers have found a way to temporarily boost its function by reprogramming liver cells to support T-cell development.

As people age, their immune system function declines. T cell populations become smaller and can't react to pathogens as ...

Flagship Pioneering, a scientific innovation engine for transformative platforms and products, today announced a research program under its strategic collaboration with Pfizer whereby Flagship-founded ...

Flagship Pioneering, a scientific innovation engine for transformative platforms and products, today announced a research program under its strategic collaboration with Pfizer whereby Flagship-founded ...

Researchers at the Johns Hopkins Kimmel Cancer Center’s Ludwig Center developed a new treatment that selectively targets ...

New data highlight liver-encoded delivery of immune modulators as a strategy to mitigate age-related immune dysfunction.

The company plans to announce Phase 1b interim data by mid-2026, and the TENACITY-01 study is expected to be completed by late 2028. This timing enables progression to Phase 2 evaluation following ...

Recent advancements in cancer vaccine development have demonstrated their potential for precise tumor targeting through ...

Janux provided a program update on its Phase 1 study of JANX008, an EGFR-targeted TRACTr, following Phase 1a completion and ...

At the recent American Society of Hematology annual meeting, phase I data highlighted a next-generation, CD19-targeted, interleukin-18-secreting "armored" CAR T-cell therapy that is designed to ...

FDA approves CBI-1214 for colorectal cancer, enabling fast-tracked clinical trials and highlighting innovative T-cell engager ...

It was the best of times, it was the worst of times for research in 2025. | It was the best of times and it was the worst of times for research in 2025. Medical breakthroughs and stunning discoveries ...